Listen to Svars' Chief Technolgy Officer present the newest addition to the iLite portfolio - CD3 effector cells and tailored CD19 target cells and hear him explain how these cells can aid in the development of bi-specific CD3 signaling therapeutic antibodies.
PRESENTATION TRACK: Characterization for Novel Biotherapeutics
TIME: Tuesday, May 3, 10:15 am EDT (16:15 CEST)
PRESENTER: Michael Schwenkert, Ph.D. - Chief Technology Officer
Bispecific antibodies efficiently trigger T-cells mediated cytotoxicity, and many T-cell-engaging biopharmaceuticals are in clinical development. Current analytical methods measuring T-cell activation are not optimal. Here we showcase an improved bioassay platform for reliable assessment of T-cell activation using CD3xCD19. Effector T-cells carry a reporter gen downstream the CD3 signaling cascade and a pair of engineered target cells is used as antigen-positive/-negative control
We will be showcasing our Fc Effector cells - iLite ADDC and our new iLite ADCP Effector cells in two posters during the poster presentation. Find out how our Fc-effector package, with uniquely engineered Effector cells and corresponding Target cells can assist you in your drug development
PRESENTER: Therese Segerstein, Portfolio Director
Stop by our booth where you will meet our team of experts and learn more about how we can our help streamline your drug development and your bioanalytical projects!